

## **Human papillomavirus vaccines. Three decent proposals**

*Juan Gérvas*

Most developed countries have introduced human papillomavirus vaccines as a public health measure. There are doubts about the effectiveness of the vaccine (1,2) and we have published asking for caution, with no policy answer (3-5). With this letter we ask now for coherence.

Cervical cancer is a problem of under-developed countries and poor (and marginalized) females in rich countries. The global real burden of the disease is in poor countries like Haiti which cannot afford a public campaign of papillomavirus vaccination.

Marketing promise us with a protection for life, with a correct vaccination.

And marketing promise us “the beginning of the end of cervical cancer”. That is, the vaccine will eliminate cervical cancer.

We can accept it and ask for a contract between public payers in developed countries which adopted de HPV vaccines and pharmaceutical industries which produce the vaccine. The contract will content three proposals:

1/ Pharmaceutical industries will donate one vaccine to under-developed countries per each vaccination done in developed countries.

2/ In case of need of re-vaccination (because less than 30 years protection) pharmaceutical industries will cover the cost of re-vaccination. And

3/ Pharmaceutical industries will cover the cost of malpractice litigation because cervical cancer in vaccinate females.

We hope public payers and pharmaceutical industries will find our proposals fair and decent.

### **References**

1. Brisson M, Velde NV, Wals PD, Boily MC. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. *CMAJ*. 2007;177:464-8.
2. Sawaya GF, Smith-McCune K. HPV vaccination: more answers more questions. *N Engl J Med*. 2007;356:1991-3.
3. Lippman A, Melnichuk R, Shimmin C, Boscope M. Human papilloma virus vaccines and women's health: questions and cautions. *CMAJ*. 2007;177:484-7.
4. Gérvas J. La incierta prevención del cáncer de cuello de útero con la vacuna contra el virus del papiloma humano. *Rev Port Clin Geral*. 2007;23:547-55.
5. Lippman A, Boscoe M, Scurfield C. Do you approve of spending \$300 on HPV vaccination? No. *Can Family Phys*. 2008;54:175-7.